Mesothelioma Trials
| ClinicalTrials.gov Identifier: |
NCT02784171 |
This study is active, but not recruiting participants.
Pembrolizumab is a new type of drug for mesothelioma (immunotherapy). Laboratory tests show that this drug works by helping improve the body's immune response to help fight cancer. Pembrolizumab may help the immune system to recognize cancer cells and slow down the growth and/or spreading of cancer.
Alberta
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
British Columbia
BCCA - Cancer Centre for the Southern Interior, Kelowna
BCCA - Fraser Valley Cancer Centre, Surrey
Manitoba
CancerCare Manitoba, Winnipeg
Ontario
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
London Regional Cancer Program, London
Ottawa Hospital Research Institute, Ottawa
University Health Network, Toronto
Quebec
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal
The Research Institute of the McGill University, Montreal
University Institute of Cardiology and Respirology of Quebec, Quebec City
Saskatchewan
Allan Blair Cancer Centre, Regina
| ClinicalTrials.gov Identifier: |
NCT03710876 |
This study is currently active but not recruiting participants.
This study will evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen.
Québec
Institut Universitaire de Cardiologie et de Pneumologie De Quebec
Québec, Sainte-Foy, Canada, G1V 4G5
Principal Investigator: Dr Simon Martel, (418) 656-2617,
[email protected]
Contact: Marie-Eve Morneau, CRC, (418) 656 8711 ext 2690,
[email protected]
| ClinicalTrials.gov Identifier: |
NCT04028570 |
This study is active but not recruiting participants.
This study aims to find the maximum tolerated dose level for malignant pleural mesothelioma patients receiving background radiation + boost radiation, and surgery. Boost radiation is an experimental form of radiation that involves targeting non-uniform high doses of radiation to bulky pleural masses.
Ontario
Princess Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT03126630 |
This study is currently active but not recruiting participants.
This phase I/II trial studies the side effects and how well pembrolizumab with or without anetumab ravtansine works in treating patients with mesothelin-positive pleural mesothelioma. Monoclonal antibodies, such as anetumab ravtansine, may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Ontario
Princess Margaret Hospital, Toronto
| ClinicalTrials.gov Identifier: |
NCT03564691 |
This study is currently active but not recruiting participants.
This study consists of several parts: dose escalation, dose expansion, dose expansion in Chinese participants residing in China, and coformulation. Dose escalation is to evaluate the safety, tolerability, and preliminary efficacy of MK-4830 monotherapy administration (Arms A and B) and in combination with pembrolizumab (Arm C). Dose expansion is to evaluate the objective response rate (ORR) of MK-4830 in combination with pembrolizumab (Arms A-F); evaluate the safety and tolerability of MK-4830 administered in combination with pembrolizumab, carboplatin, and pemetrexed (Arm G) and of MK-4830 administered in combination with pembrolizumab and lenvatinib (Arm H); evaluate the safety, tolerability and ORR of MK-4830 in combination with pembrolizumab plus chemotherapy (Arms I-L); and evaluate the safety and tolerability of MK-4830 in combination with pembrolizumab in Chinese participants from China (Arm M). The coformulation part (Arm N) evaluates the safety and tolerability of MK-4830A (coformulation of MK-4830 800 mg + pembrolizumab 200 mg). There is no formal hypothesis testing in this study.
Ontario
Hamilton
Ottawa
Toronto